Biomea Fusion (BMEA) closed at $0.59 on November 19, 2026, up 11.0% from the previous close, on volume of 935,979 shares (30-day average 2,095,099).
Data as of November 19, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
Biomea Fusion to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 12-Nov 4:01 PM ET)
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
Globe Newswire (Tue, 10-Nov 4:05 PM ET)
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Globe Newswire (Tue, 13-Oct 4:08 PM ET)
Globe Newswire (Mon, 12-Oct 4:30 PM ET)
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
Globe Newswire (Wed, 23-Sep 7:03 AM ET)
Biomea Fusion Announces Proposed Public Offering of Securities
Globe Newswire (Tue, 22-Sep 4:05 PM ET)
Market Chameleon (Tue, 25-Aug 7:08 AM ET)
Market Chameleon (Mon, 24-Aug 6:30 AM ET)
Globe Newswire (Mon, 24-Aug 7:00 AM ET)
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Biomea Fusion trades on the NASDAQ stock market under the symbol BMEA.
As of November 20, 2026, BMEA stock price declined to $0.57 with 1,119,363 million shares trading.
BMEA has a beta of 3.00, meaning it tends to be more sensitive to market movements. BMEA has a correlation of 0.12 to the broad based SPY ETF.
BMEA has a market cap of $41.75 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BMEA traded as high as $22.74 and as low as $.45.
The top ETF exchange traded funds that BMEA belongs to (by Net Assets): VTI, VXF, IWC, BUSM.
BMEA has underperformed the market in the last year with a return of -47.8%, while the SPY ETF gained +5.3%. In the last 3 month period, BMEA fell short of the market, returning -58.7%, while SPY returned -10.0%. However, in the most recent 2 weeks BMEA has outperformed the stock market by returning -2.2%, while SPY returned -5.8%.
BMEA support price is $.54 and resistance is $.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMEA shares will trade within this expected range on the day.